梁啟銘 特聘研究員

2006-迄今

國立中興大學 兼任教授

2006-迄今

國家衛生研究院特聘研究員暨主任秘書

1997 -

研究員兼公共事務及科技移轉主任, 中央研究院

1990 - 1994

分子免疫主任, 美國 Oncologix 生技公司

1987 - 1990

免疫室代主任, 美國FDA Retrovirology Branch

1986 - 1987

資深科學家, 美國 Biogen生技公司

1982 - 1986

免疫主任, 瑞士Biogen生技公司

-

研究員兼公共事務及科技移轉主任, 中央研究院

我的實驗室主要是探討具生物活性的分子之作用機轉及對生物體之影響。比方說口蹄疫病毒(FMDV)是偶蹄動物(如豬牛等)的重大傳染病原但對人體並不會產生太大傷害。最近我們發現利用純化技術所得到的口蹄疫病毒之重組VP1蛋白質(rVP1， 0.3 μM) 可以在天竺鼠BHK-21細胞引起DNA聚集及碎裂的現象而導致計劃性細胞死亡(apoptosis)。rVP1也會在人類胸腺癌細胞(MCF-7)及攝護腺癌細胞(PC-3)引起計劃性細胞死亡。我們對於rVP1之致死機制也加以探討並已經有充分之瞭解曉得rVP1乃是經結合到細胞的integrin後經由阻礙Akt/GSK-3b/caspase的訊息傳遞過程而引起計劃性細胞死亡。另一例子CpG ODN我們最近發現它可造成細胞不致產生計劃性細胞死亡。而此功能與它能與Toll-like receptor 9 (TLR-9) 結合而增進heat shock proteins(Hsp)之表達有關。不同之Hsp又有不同的作用機轉以防止計劃性細胞死亡

Liang, C.-M., Liang, C.-M., Jost, T., Sand, A. Dougas, I, and Allet, B. Production and characterization of monoclonal antibodies against recombinant human tumor necrosis factor/cachectim. Biochem. Biophys. Res. Commun. 137, 847-854, 1986.

Liang, C.-M., Lee, N., Cattell, D., and Liang, C.-M. Glutathione regulates interleukin-2 activity on cytotoxic T-cells. J. Biol. Chem. 264, 13519-13523, 1989.

Johnston, P.G., Liang, C.-M., Henry, S., Chabner, B.A., and Allegra, C.J. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human-cell and tissue. Cancer Res. 51, 6668-6676, 1991.

Hoythuya, M., Fridman, R., Komarek, D., porter-Jordan, K., Stetler-Stevenson, W.G., Liotta, L.A., and Liang, C.-M. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int. J. Cancer 56, 500-505, 1994.

Peng, J.-M., Liang, C.-M. and Liang, C.-M. VP1 of foot-and-mouth disease virus induces apoptosis via akt signaling pathway. J. Biol. Chem. 279, 52168, 2004.

Kuo, C.-C., Lin, W.-T., Liang, C.-M., and Liang, C.-M. Class I and III phosphatidylinositol 3’-kinase play distinct roles in toll-like receptor signaling pathway. J. Immunol. 176: 5943-5949, 2006.

Kuo, C.-C., Liang, C.-M, and Liang, C.-M. CpG-B ODN promotes cell survival via up-regulation of heat-shock protein 70. J. Biol. Chem. 281, 38200, 2006.

CA Patent No. 2,109,086 “Monoclonal antibodies specific for human thymidylate synthase”; Granted 1992.

AU Patent No. 43,739,939 “Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors”; Granted 1993.

US Patent No. 5,866,570 “Treatment of vascular leakage and related syndrome such as septic shock by administration of matrix metalloproteinase inhibitors”; Granted 1999.

US Patent No. 6,221,620 “Monoclonal antibodies specific for human thymidylate synthase”; Granted 2001.